U.S. stock futures are edging mostly higher as investors watch corporate earnings, Honeywell plans to split into three companies, and Qualcomm stock drops as its licensing revenue misses expectations.

The Dow Jones Industrial Average ( ^DJI) fell 0.3%. The S&P 500 ( ^GSPC) rose more than 0.3%, and the tech-heavy Nasdaq Composite ( ^IXIC) popped 0.5% on the heels of two winning days in a row for the ...

Real-time index price for TSX Financials Capped Index (TTFS), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

S&P 500 E-Mini futures are up +0.05%, andMarch Nasdaq 100 E-Mini futures are down -0.08% this morning as investors awaited a new round of U.S. economic data, remarks from Fe ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

BofA analyst Tim Anderson raised the firm’s price target on Eli Lilly (LLY) to $1,000 from $997 and keeps a Buy rating on the shares after ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the ...

Stay updated on the latest stock market trends and company earnings. Discover the impact of market gains and profit reports ...

Shares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 ...

Eli Lilly's sales growth is coming short of expectations, which is a problem considering its valuation. The company does have a vast lineup and a deep pipeline that go beyond diabetes and obesity.